Art. -Nr.: HY-14393

Emodin

(Synonyms: Frangula emodin)

42 Cited Publications

Kundenbewertung

Based on 42 publication(s) in Google Scholar

Emodin (Frangula emodin), an anthraquinone derivative, is an anti-SARS-CoV compound. Emodin blocks the SARS coronavirus spike protein and angiotensin-converting enzyme 2 (ACE2) interaction. Emodin inhibits casein kinase-2 (CK2). Anti-inflammatory and anticancer effects. Emodin is a potent selective 11β-HSD1 inhibitor with the IC₅₀ of 186 and 86 nM for human and mouse 11β-HSD1, respectively. Emodin ameliorates metabolic disorder in diet-induced obese mice.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.25%
CAS. Nr.: 518-82-1
Formel: C₁₅H₁₀O₅
Molecular Weight:270.24

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 1 year , -20°C, 6 months

Emodin Chemical Structure

CAS. Nr.: 518-82-1

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (42)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

Emodin (Frangula emodin), an anthraquinone derivative, is an anti-SARS-CoV compound. Emodin blocks the SARS coronavirus spike protein and angiotensin-converting enzyme 2 (ACE2) interaction^[1]. Emodin inhibits casein kinase-2 (CK2). Anti-inflammatory and anticancer effects^[2]. Emodin is a potent selective 11β-HSD1 inhibitor with the IC₅₀ of 186 and 86 nM for human and mouse 11β-HSD1, respectively. Emodin ameliorates metabolic disorder in diet-induced obese mice^[3].

IC₅₀ & Target^[1]^[2]^[3]

SARS-CoV

CK2α Wild-type

1.4 μM (IC₅₀, at ATP concentration is 10 μM)

CK2α Wild-type

5.9 μM (IC₅₀, at ATP concentration is 50 μM)

mouse 11β-HSD1

86 nM (IC₅₀)

human 11β-HSD1

186 nM (IC₅₀)

Alle Casein Kinase Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
A-375	IC₅₀	44.91 μM Compound: Emodin	Cytotoxicity against human A375 cells measured after 24 hrs by MTT assay Cytotoxicity against human A375 cells measured after 24 hrs by MTT assay	[PMID: 27769031]
A549	CC₅₀	30.7 μM Compound: 25, CACDB1751080	Cytotoxicity against human A549 cells after 48 hrs Cytotoxicity against human A549 cells after 48 hrs	[PMID: 20108931]
A549	EC₅₀	10.9 μM Compound: 25, CACDB1751080	Antiviral activity against Dengue virus type 2 infected in human A549 cells assessed as decrease in viral E protein production by cell-based flavivirus immunodetection assay Antiviral activity against Dengue virus type 2 infected in human A549 cells assessed as decrease in viral E protein production by cell-based flavivirus immunodetection assay	[PMID: 20108931]
A549	EC₅₀	19 μM Compound: 4	Phototoxicity against human A549 cells assessed as reduction in cell growth preincubated with compound for 24 hrs under dark condition and measured after 48 hrs by SRB assay Phototoxicity against human A549 cells assessed as reduction in cell growth preincubated with compound for 24 hrs under dark condition and measured after 48 hrs by SRB assay	[PMID: 37708055]
A549	EC₅₀	2.9 μM Compound: 4	Phototoxicity against human A549 cells assessed as reduction in cell growth preincubated with compound for 24 hrs followed by blue light irradiation at 468 nm for 7 mins 30 sec and measured after 48 hrs by SRB assay Phototoxicity against human A549 cells assessed as reduction in cell growth preincubated with compound for 24 hrs followed by blue light irradiation at 468 nm for 7 mins 30 sec and measured after 48 hrs by SRB assay	[PMID: 37708055]
A549	ED₅₀	4.2 μg/mL Compound: Emodin	Cytotoxicity against human A549 cells Cytotoxicity against human A549 cells	[PMID: 2778455]
A549	IC₅₀	28 μM Compound: 29	Cytotoxicity against human A549 cells after 72 hrs by MTT assay Cytotoxicity against human A549 cells after 72 hrs by MTT assay	[PMID: 21696954]
AGS	EC₅₀	>25 μM Compound: 4	Phototoxicity against human AGS cells assessed as reduction in cell growth preincubated with compound for 24 hrs under dark condition and measured after 48 hrs by SRB assay Phototoxicity against human AGS cells assessed as reduction in cell growth preincubated with compound for 24 hrs under dark condition and measured after 48 hrs by SRB assay	[PMID: 37708055]
AGS	EC₅₀	1.5 μM Compound: 4	Phototoxicity against human AGS cells assessed as reduction in cell growth preincubated with compound for 24 hrs followed by blue light irradiation at 468 nm for 7 mins 30 sec and measured after 48 hrs by SRB assay Phototoxicity against human AGS cells assessed as reduction in cell growth preincubated with compound for 24 hrs followed by blue light irradiation at 468 nm for 7 mins 30 sec and measured after 48 hrs by SRB assay	[PMID: 37708055]
AGS	IC₅₀	>70 μM Compound: 1, Emodin	Cytotoxicity against human AGS cells assessed as cell viability after 24 hrs by MTT assay Cytotoxicity against human AGS cells assessed as cell viability after 24 hrs by MTT assay	[PMID: 22901410]
B16	IC₅₀	>100 μM Compound: emodin	Cytotoxicity against mouse B16 cells Cytotoxicity against mouse B16 cells	[PMID: 17408812]
BALB/3T3	IC₅₀	32 μg/mL Compound: Emodin	Cytotoxicity against mouse BALB/3T3 cells assessed as growth inhibition after 48 hrs by Alamar blue assay Cytotoxicity against mouse BALB/3T3 cells assessed as growth inhibition after 48 hrs by Alamar blue assay	[PMID: 23534483]
BGC-823	IC₅₀	>50 μM Compound: Emodin	Cytotoxicity against human BGC823 cells measured after 24 hrs by MTT assay Cytotoxicity against human BGC823 cells measured after 24 hrs by MTT assay	[PMID: 27769031]
Caco-2	CC₅₀	>800 μM Compound: 6	Cytotoxicity against human Caco2 cells measured after 72 hrs by MTT assay Cytotoxicity against human Caco2 cells measured after 72 hrs by MTT assay	[PMID: 27933892]
Calu-1	IC₅₀	6.25 μM Compound: 10	Inhibition of human Calu1 cell proliferation assessed as [3H]thymidine incorporation after 3 days by scintillation counting Inhibition of human Calu1 cell proliferation assessed as [3H]thymidine incorporation after 3 days by scintillation counting	[PMID: 11374975]
DLD-1	IC₅₀	28 μM Compound: Emodin	Inhibition of PRL-3-mediated cell migration in human DLD1 cells after 15 hrs by crystal violet staining based microscopic assay Inhibition of PRL-3-mediated cell migration in human DLD1 cells after 15 hrs by crystal violet staining based microscopic assay	[PMID: 22137788]
DLD-1	IC₅₀	35 μM Compound: Emodin	Inhibition of PRL-3-mediated cell invasion in human DLD1 cells after 20 hrs using crystal violet staining by Matrigel invasion assay Inhibition of PRL-3-mediated cell invasion in human DLD1 cells after 20 hrs using crystal violet staining by Matrigel invasion assay	[PMID: 22137788]
DU-145	IC₅₀	2.02 μM Compound: Emodin	Cytotoxicity against human DU145 cells assessed as cell growth inhibition after 72 hrs by Alamar blue assay Cytotoxicity against human DU145 cells assessed as cell growth inhibition after 72 hrs by Alamar blue assay	[PMID: 27173800]
HCT-116	IC₅₀	3.8 μM Compound: 12, NSC 408120	Growth inhibition of human HCT116 cells overexpressing PI3Kalpha H1047R mutant after 48 hrs by MTT assay Growth inhibition of human HCT116 cells overexpressing PI3Kalpha H1047R mutant after 48 hrs by MTT assay	[PMID: 22212721]
HCT-116	IC₅₀	5.3 μM Compound: 12, NSC 408120	Growth inhibition of human HCT116 cells overexpressing PI3Kalpha after 48 hrs by MTT assay Growth inhibition of human HCT116 cells overexpressing PI3Kalpha after 48 hrs by MTT assay	[PMID: 22212721]
HCT-116	IC₅₀	5.7 μM Compound: 3	Cytotoxicity against MDR1 Pgp under-expressing human HCT116 cells after 24 hrs by MTT assay Cytotoxicity against MDR1 Pgp under-expressing human HCT116 cells after 24 hrs by MTT assay	[PMID: 17949858]
HCT-116	IC₅₀	6.2 μM Compound: 12, NSC 408120	Growth inhibition of human HCT116 cells after 48 hrs by MTT assay Growth inhibition of human HCT116 cells after 48 hrs by MTT assay	[PMID: 22212721]
HEK293	IC₅₀	1.3 μM Compound: Emodin	Cytotoxicity against human HEK293 cells after 2 days by alamar blue assay Cytotoxicity against human HEK293 cells after 2 days by alamar blue assay	[PMID: 22093761]
HeLa	IC₅₀	15.6 μM Compound: 10	Inhibition of human HeLa cell proliferation assessed as [3H]thymidine incorporation after 3 days by scintillation counting Inhibition of human HeLa cell proliferation assessed as [3H]thymidine incorporation after 3 days by scintillation counting	[PMID: 11374975]
HepG2	IC₅₀	>50 μM Compound: Emodin	Cytotoxicity against human HepG2 cells measured after 24 hrs by MTT assay Cytotoxicity against human HepG2 cells measured after 24 hrs by MTT assay	[PMID: 27769031]
HepG2	IC₅₀	>70 μM Compound: 1, Emodin	Cytotoxicity against human HepG2 cells assessed as cell viability after 24 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as cell viability after 24 hrs by MTT assay	[PMID: 22901410]
HepG2	IC₅₀	1.7 μM Compound: 8	Cytotoxicity against human HepG2 cells after 6 days by MTT assay Cytotoxicity against human HepG2 cells after 6 days by MTT assay	[PMID: 29786436]
HepG2	IC₅₀	13.1 μM Compound: Emodin	Cytotoxicity against human HepG2 cells after 2 days by alamar blue assay Cytotoxicity against human HepG2 cells after 2 days by alamar blue assay	[PMID: 22093761]
HepG2	IC₅₀	5.2 μM Compound: 3	Cytotoxicity against MDR1 Pgp overexpressing human HepG2 cells after 24 hrs by MTT assay Cytotoxicity against MDR1 Pgp overexpressing human HepG2 cells after 24 hrs by MTT assay	[PMID: 17949858]
HepG2	IC₅₀	55.1 μM Compound: emodin	Cytotoxicity against human HepG2 cells Cytotoxicity against human HepG2 cells	[PMID: 17408812]
HL-60	IC₅₀	>20 μM Compound: Emodin	Cytotoxicity against human HL60 cells after 72 hrs by MTT assay Cytotoxicity against human HL60 cells after 72 hrs by MTT assay	[PMID: 20561793]
HT-29	ED₅₀	>10 μg/mL Compound: Emodin	Cytotoxicity against human HT-29 cells Cytotoxicity against human HT-29 cells	[PMID: 2778455]
K562	IC₅₀	>100 μM Compound: 10	Inhibition of human K562 cell proliferation assessed as [3H]thymidine incorporation after 3 days by scintillation counting Inhibition of human K562 cell proliferation assessed as [3H]thymidine incorporation after 3 days by scintillation counting	[PMID: 11374975]
KB	ED₅₀	3.46 μg/mL Compound: 3	Cytotoxicity against human KB cells Cytotoxicity against human KB cells	10.1021/np50085a021
KB	IC₅₀	>20 μM Compound: Emodin	Cytotoxicity against human KB cells after 72 hrs by MTT assay Cytotoxicity against human KB cells after 72 hrs by MTT assay	[PMID: 20561793]
Lewis lung carcinoma cell line	IC₅₀	>100 μM Compound: emodin	Cytotoxicity against mouse LLC cells Cytotoxicity against mouse LLC cells	[PMID: 17408812]
LoVo	IC₅₀	27 μM Compound: 29	Cytotoxicity against human LoVo cells after 72 hrs by MTT assay Cytotoxicity against human LoVo cells after 72 hrs by MTT assay	[PMID: 21696954]
MCF7	IC₅₀	317.4 μM Compound: 14	Cytotoxicity against human MCF7 cells after 48 hrs by PrestoBlue cell viability assay Cytotoxicity against human MCF7 cells after 48 hrs by PrestoBlue cell viability assay	[PMID: 25226568]
MDA-MB-231	IC₅₀	>20 μM Compound: Emodin	Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay	[PMID: 20561793]
Panel NCI-60 (60 carcinoma cell lines)	GI₅₀	10 μM Compound: Emodin	Growth inhibitory activity against human cancer cell line in the NCI's anticancer drug screening program Growth inhibitory activity against human cancer cell line in the NCI's anticancer drug screening program	[PMID: 15743190]
PC-3	IC₅₀	35 μM Compound: 29	Cytotoxicity against human PC3 cells after 72 hrs by MTT assay Cytotoxicity against human PC3 cells after 72 hrs by MTT assay	[PMID: 21696954]
PLC-PRF-5	ED₅₀	5.91 μg/mL Compound: 3	Cytotoxicity against human PLC/PRF/5 cells Cytotoxicity against human PLC/PRF/5 cells	10.1021/np50085a021
Raji	IC₅₀	43.8 μM Compound: 10	Inhibition of human Raji cell proliferation assessed as [3H]thymidine incorporation after 3 days by scintillation counting Inhibition of human Raji cell proliferation assessed as [3H]thymidine incorporation after 3 days by scintillation counting	[PMID: 11374975]
SGC-7901	IC₅₀	5.6 μM Compound: 8	Cytotoxicity against human SGC7901 cells after 6 days by MTT assay Cytotoxicity against human SGC7901 cells after 6 days by MTT assay	[PMID: 29786436]
SGC-7901	IC₅₀	61.3 μM Compound: Emodin	Cytotoxicity against human SGC7901 cells after 2 days by alamar blue assay Cytotoxicity against human SGC7901 cells after 2 days by alamar blue assay	[PMID: 22093761]
SK-MEL-28	IC₅₀	35 μM Compound: 29	Cytotoxicity against human SK-MEL-28 cells after 72 hrs by MTT assay Cytotoxicity against human SK-MEL-28 cells after 72 hrs by MTT assay	[PMID: 21696954]
T-24	EC₅₀	>25 μM Compound: 4	Phototoxicity against human T24 cells assessed as reduction in cell growth preincubated with compound for 24 hrs under dark condition and measured after 48 hrs by SRB assay Phototoxicity against human T24 cells assessed as reduction in cell growth preincubated with compound for 24 hrs under dark condition and measured after 48 hrs by SRB assay	[PMID: 37708055]
T-24	EC₅₀	1.7 μM Compound: 4	Phototoxicity against human T24 cells assessed as reduction in cell growth preincubated with compound for 24 hrs followed by blue light irradiation at 468 nm for 7 mins 30 sec and measured after 48 hrs by SRB assay Phototoxicity against human T24 cells assessed as reduction in cell growth preincubated with compound for 24 hrs followed by blue light irradiation at 468 nm for 7 mins 30 sec and measured after 48 hrs by SRB assay	[PMID: 37708055]
THP-1	IC₅₀	32 μg/mL Compound: Emodin	Cytotoxicity against human THP1 cells assessed as growth inhibition after 48 hrs by Alamar blue assay Cytotoxicity against human THP1 cells assessed as growth inhibition after 48 hrs by Alamar blue assay	[PMID: 23534483]
U-373MG ATCC	IC₅₀	31 μM Compound: 29	Cytotoxicity against human U373 cells after 72 hrs by MTT assay Cytotoxicity against human U373 cells after 72 hrs by MTT assay	[PMID: 21696954]
Vero	IC₅₀	40 μM Compound: 10	Inhibition of african green monkey Vero cell proliferation assessed as [3H]thymidine incorporation after 3 days by scintillation counting Inhibition of african green monkey Vero cell proliferation assessed as [3H]thymidine incorporation after 3 days by scintillation counting	[PMID: 11374975]
Vero C1008	CC₅₀	68.6 μM Compound: 50	Cytotoxicity against African green monkey Vero E6 cells measured up to 24 to 72 hrs by MTT assay Cytotoxicity against African green monkey Vero E6 cells measured up to 24 to 72 hrs by MTT assay	[PMID: 31549836]
Vero C1008	IC₅₀	3.2 μM Compound: 50	Antiviral activity against Zika virus infected in African green monkey Vero E6 cells assessed as reduction in virus infectivity preincubated with virus for 1 hr followed by cell infection and measured after 96 hrs by crystal violet staining based assay Antiviral activity against Zika virus infected in African green monkey Vero E6 cells assessed as reduction in virus infectivity preincubated with virus for 1 hr followed by cell infection and measured after 96 hrs by crystal violet staining based assay	[PMID: 31549836]
WISH	IC₅₀	28.8 μM Compound: 10	Inhibition of human WISH cell proliferation assessed as [3H]thymidine incorporation after 3 days by scintillation counting Inhibition of human WISH cell proliferation assessed as [3H]thymidine incorporation after 3 days by scintillation counting	[PMID: 11374975]

In Vitro

Emodin (10-400 μM) blocks the binding of S protein to ACE2 in a dose-dependent manner with the IC₅₀ value of 200 μM^[1].
Emodin (5-50 μM) inhibits the S protein-pseudotyped retrovirus infectivity in a dose-dependent manner. Emodin blocks the SARS-CoV S protein binding to Vero E6 cells^[1].
Emodin inhibits casein kinase-2 (CK2) with IC₅₀s of 5.9, 30.0, and 7.1 μM for CK2α Wild-type, Ile174Ala mutant, and His160Ala mutant at ATP concentration is 50 μM, respectively. The IC₅₀s are 1.40 and 38.00 μM for CK2α Wild-type, and Val66Ala mutant at ATP concentration is 10 μM^[2].
Emodin exhibits low inhibitory activity against mouse and human 11β-hydroxysteroid dehydrogenase type 2 (11β-HSD2), with an IC₅₀ higher than 1 mM, indicating that Emodin is more than 5000-fold selective for the human and mouse 11β-HSD1 enzymes over the type 2 isoenzyme^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[1]

Cell Line:

Vero E6 cells transfected with the plasmid encoding ACE2
Concentration:

0, 5, 25, 50 μM
Incubation Time:

24 hours
Result:

Vero cells treated with 50 μM remained 82.4±3.8% viability, the anti-SARS-CoV activity was not due to toxicity.

In Vivo

Emodin (single oral administration of 100 or 200 mg/kg) inhibits 11β-HSD1 activity in normal C57BL/6J male mice^[3].
Emodin (100 mg/kg; oral administration; b.i.d.) improves insulin sensitivity and lipid metabolism, and lowers blood glucose and hepatic PEPCK, and glucose-6-phosphatase mRNA in diet-induced obese (DIO) mice^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

C57BL/6J male mice^[3]
Dosage:

100 or 200 mg/kg
Administration:

Acute administered p.o. ; Two hours later, the mice were killed by cervical dislocation,
Result:

Significantly inhibited liver 11β-HSD1 enzymatic activity by 17.6 and 31.3% and mesenteric fat 11β-HSD1 enzymatic activity by 21.5 and 46.7% at 100 or 200 mg/kg, respectively.

Animal Model:

DIO mice (C57BL/6J male mice were fed a formulated research diet)^[3]
Dosage:

100 mg/kg
Administration:

Oral gavage; twice per day; for 35 days
Result:

Reduced fasting glucose concentrations to 77.2% of the vehicle control mice after 7 days of treatment, and these remained significantly lower throughout the treatment period.
Exhibited a significant reduction in blood glucose levels at all time-points following oral glucose challenge after 24 days of treatment.
Evoked a significantly greater reduction in blood glucose values 40 and 90 min after insulin injection after 28 days of treatment.
The serum insulin level was also significantly reduced, to 66.2% of control mice, after 35 days of treatment.
Improved the lipid profiles. The serum triglyceride and total cholesterol levels were significantly reduced by 19.3 and 12.5% after 35 days of treatment, respectively.
Caused a 22.7% reduction of non-esterified free fatty acid (NEFA) level.
Lowered body weight and appetite from day 18 of the treatment; their body weights were reduced by 13.9% at the end of treatment.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS. Nr. 518-82-1
Appearance Solid
Molecular Weight 270.24
Formel C₁₅H₁₀O₅
Color Yellow to orange
SMILES

O=C1C2=C(C=C(C)C=C2O)C(C3=CC(O)=CC(O)=C31)=O
Synonyms

Frangula emodin
Structure Classification
- Quinones
- Anthraquinones
- Phenols
- Polyphenols
Initial Source
- Endogenous metabolite
- Human Gut Microbiota Metabolites
- Microorganisms
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	1 year
	-20°C	6 months

Publications (42)

All Bio/Physico-chemical AssayFlow CytometryWBHistological Imaging/StainingCell Proliferation/Viability AssayRT-PCRIF

Sort by:

Journal Impact Factor

Nucleic Acids Res

COVID19 Drug Repository: text-mining the literature in search of putative COVID19 therapeutics. [Abstract]

2021 Jan 8;49(D1):D1113-D1121. PMID: 33166390
Adv Sci (Weinh)

Emodin Alleviates Sepsis-Induced Multiorgan Damage by Inhibiting NETosis through Targeting Neutrophils BCL-10. [Abstract]

2025 Aug 8:e17129. PMID: 40779122

Emodin purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Aug 8:e17129. [Abstract]

Kaplan–Meier survival curves over a 7-day period comparing the Sham, CLP septic group, Emodin treatment group, and DXMS (intraperitoneal injections of 2 mg/kg DXMS twice daily at 200 μL per dose) treatment group.

Emodin purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Aug 8:e17129. [Abstract]

Histopathological images showing tissue morphology and injury in the lung (C), liver (D), spleen (E), and kidney (F) across the four experimental groups.

Emodin purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Aug 8:e17129. [Abstract]

CCK-8 assay to evaluate the effect of Emodin on the viability of dHL-60 cells, dHL-60 cells after PMA induction, and Dichlorodihydrofluorescein diacetate (DCFH-DA) probe detection of ROS activity in dHL-60 cells after PMA induction, with or without Emodin treatment.
Pharmacol Res

Genetic and pharmacological targeting of HINT2 promotes OXPHOS to alleviate inflammatory responses and cell necrosis in acute pancreatitis. [Abstract]

2025 Jan 21:212:107620. PMID: 39848351
Phytomedicine

From virtual screening to functional discovery: Apigenin ameliorates acute pancreatitis by targeting HINT2 to regulate the mitochondrial acetylome. [Abstract]

2026 Mar:152:157826. PMID: 41579589
Phytomedicine

Bruceantin inhibits the c-Myc/RL27A axis to suppress tumor progression in hepatocellular carcinoma. [Abstract]

2025 Dec 24:150:157740. PMID: 41477978
Phytomedicine

Fangchinoline suppresses nasopharyngeal carcinoma progression by inhibiting SQLE to regulate the PI3K/AKT pathway dysregulation. [Abstract]

2025 May:140:156484. PMID: 40090046
J Hazard Mater

Silicon carbide nanoparticles induce pulmonary fibrosis by promoting macrophage apoptosis through parkin-mediated mitophagy disruption and the intervention effect of emodin. [Abstract]

2026 Apr 1:507:141765. PMID: 41864028
Acta Pharmacol Sin

Osimertinib successfully combats EGFR-negative glioblastoma cells by inhibiting the MAPK pathway. [Abstract]

2021 Jan;42(1):108-114. PMID: 32398685
Apoptosis

Emodin induces ferroptosis in colorectal cancer through NCOA4-mediated ferritinophagy and NF-κb pathway inactivation. [Abstract]

2024 Oct;29(9-10):1810-1823. PMID: 38704789
Phytother Res

Emodin Promotes Peripheral Nerve Repair by Modulating Inflammasome Activation Through Autophagy via the EGFR/PI3K/AKT/mTOR Pathway. [Abstract]

2025 Mar 26. PMID: 40135386
Phytother Res

Emodin alleviates CRS4-induced mitochondrial damage via activation of the PGC1α signaling. [Abstract]

2024 Mar;38(3):1345-1357. PMID: 38198804
Fertil Steril

Protein kinase CK2 participates in estrogen-mediated endothelial progenitor cell homing to endometriotic lesions through stromal cells in a stromal cell-derived factor-1- CXCR4-dependent manner. [Abstract]

2020 May;113(5):1067-1079.e5. PMID: 32386617
Am J Chin Med

Emodin Inhibitsg Hepatocellular Carcinoma Invasion and Migration by Regulating the HDAC4/NF-κB (p65)/CXCL12 Signaling Axis and Suppressing M2 Macrophage Polarization. [Abstract]

2026 Apr 25:1-33. PMID: 42036631
Redox Rep

Ferroptosis inhibition and mitochondrial rescue: a novel mechanism of emodin in rheumatoid arthritis. [Abstract]

2026 Dec 31;31(1):2646383. PMID: 41866335
Drug Des Devel Ther

Emodin Alleviates Monocrotaline-Induced Pulmonary Arterial Hypertension by Directly Targeting TAK1. [Abstract]

2025 Sep 30:19:8843-8864. PMID: 41049040
J Inflamm (Lond)

Emodin alleviates intestinal ischemia-reperfusion injury through antioxidant stress, anti-inflammatory responses and anti-apoptosis effects via Akt-mediated HO-1 upregulation. [Abstract]

2024 Jul 9;21(1):25. PMID: 38982499
Pharmaceuticals (Basel)

Bruceine D Identified as a Drug Candidate against Breast Cancer by a Novel Drug Selection Pipeline and Cell Viability Assay. [Abstract]

2022 Jan 31;15(2):179. PMID: 35215292
Int J Mol Sci

Emodin Attenuates Rheumatoid Arthritis by Modulating the NF-κB/HIF-1α/VEGF Signaling Pathway. [Abstract]

2026 Apr 12;27(8):3460. PMID: 42074103
Int Immunopharmacol

Emodin facilitates the transformation of A1/A2 reactive astrocytes through the 11β-HSD1/AKT signaling pathway in the context of cerebral ischemia. [Abstract]

2025 Sep 27:166:115628. PMID: 41016200
Int Immunopharmacol

Emodin delays rheumatoid arthritis progression by inhibiting the ROS/TXNIP/NLRP3 signaling pathway. [Abstract]

2025 May 18:158:114861. PMID: 40388860
Int Immunopharmacol

Emodin attenuates silica-induced lung injury by inhibition of inflammation, apoptosis and epithelial-mesenchymal transition. [Abstract]

2021 Feb:91:107277. PMID: 33352442
Int Immunopharmacol

Emodin improves alveolar hypercoagulation and inhibits pulmonary inflammation in LPS-provoked ARDS in mice via NF-κB inactivation. [Abstract]

2020 Nov;88:107020. PMID: 33182048
J Enzyme Inhib Med Chem

Integrating virtual screening and molecular dynamics simulations to identify emodin as a PYCR1 inhibitor modulating docetaxel sensitivity in prostate cancer. [Abstract]

2026 Dec;41(1):2622725. PMID: 41665114
J Cell Mol Med

Emodin combined with 5-aminolevulinic acid photodynamic therapy inhibits condyloma acuminate angiogenesis by targeting SerRS. [Abstract]

2024 Oct;28(19):e70122. PMID: 39351642

Emodin purchased from MedChemExpress. Usage Cited in: J Cell Mol Med. 2024 Oct;28(19):e70122. [Abstract]

SiHa cells were treated for 24 h, 48 h and 72 h with Emodin at 0, 10, 20, 30, 40 and 50 μmol/L concentrations, and SiHa cells viability was measured with CCK‐8 assay.

Emodin purchased from MedChemExpress. Usage Cited in: J Cell Mol Med. 2024 Oct;28(19):e70122. [Abstract]

SiHa cells were treated for 24 h with Emodin at 0, 5, 10 and 20 μmol/L concentrations and SiHa cells apoptosis rate was measured with Flow cytometry assay.

Emodin purchased from MedChemExpress. Usage Cited in: J Cell Mol Med. 2024 Oct;28(19):e70122. [Abstract]

After different concentrations Emodin (0-20 μmol/L) treated SiHa cells 24 h, the apoptosis marker was detected with Western blot.

Emodin purchased from MedChemExpress. Usage Cited in: J Cell Mol Med. 2024 Oct;28(19):e70122. [Abstract]

Western blot analysis displayed the expression of SerRS and VEGFA in SiHa cells treated with 1, 5, 10, 20 and 40 μmol/L Emodin.

Emodin purchased from MedChemExpress. Usage Cited in: J Cell Mol Med. 2024 Oct;28(19):e70122. [Abstract]

Real‐time PCR showed the level of SerRS in SiHa cells treated with 1, 5, 10, 20 and 40 μmol/L Emodin. GAPDH was used as a loading control.
Fish Shellfish Immunol

Emodin enhances host antiviral immunity against Micropterus salmoides rhabdovirus by activating RLR signaling in largemouth bass. [Abstract]

2025 Aug 6:166:110633. PMID: 40769268
Curr Issues Mol Biol

Investigating the Mechanism of Emodin in Rheumatoid Arthritis Through the HIF-1α/NLRP3 Pathway and Mitochondrial Autophagy. [Abstract]

2025 Jun 25;47(7):486. PMID: 40728955
J CHEM-NY

2023 Feb 4.
Int J Parasitol Drugs Drug Resist

Evaluation of the inhibitory effects of emodin on Neospora caninum invasion and proliferation in vitro. [Abstract]

2025 Dec:29:100624. PMID: 41187614
Mol Carcinog

Blocking the ATR-SerRS-VEGFA pathway targets angiogenesis for UV-induced cutaneous squamous cell carcinoma. [Abstract]

2024 Jun;63(6):1160-1173. PMID: 38695641
Hum Exp Toxicol

Emodin protects against apoptosis and inflammation by regulating reactive oxygen species-mediated NF- κ B signaling in interleukin-1 β-stimulated human nucleus pulposus cells. [Abstract]

2023 Jan-Dec:42:9603271221138552. PMID: 36598795
Exp Cell Res

Network-based analysis with primary cells reveals drug response landscape of acute myeloid leukemia. [Abstract]

2020 Aug 1;393(1):112054. PMID: 32376287
Surgery

Emodin alleviates intestinal ischemia/reperfusion-induced lung injury by upregulating HO-1 expression via PI3K/AkT pathway. [Abstract]

2024 May 28:S0039-6060(24)00230-7. PMID: 38811326
Tissue Cell

Emodin suppresses adipogenesis of bone marrow derived mesenchymal stem cells from aplastic anemia via increasing TRIB3 expression. [Abstract]

2024 Feb:86:102287. PMID: 38086146
BMC Pulm Med

Emodin inhibits viability, proliferation and promotes apoptosis of hypoxic human pulmonary artery smooth muscle cells via targeting miR-244-5p/DEGS1 axis. [Abstract]

2021 Jul 31;21(1):252. PMID: 34332565
Biomed Res Int

Anti-influenza A Virus Effects and Mechanisms of Emodin and Its Analogs via Regulating PPAR α/ γ-AMPK-SIRT1 Pathway and Fatty Acid Metabolism. [Abstract]

2021 Sep 9;2021:9066938. PMID: 34540999
Vet Microbiol

The Chinese medicine monomer Schisandrin C inhibits PRRSV infection by regulating the OGT-PI3K/AKT/mTOR signaling pathway. [Abstract]

2026 May:316:110992. PMID: 41865607
Clin Respir J

Emodin alleviates lung ischemia-reperfusion injury by suppressing gasdermin D-mediated pyroptosis in rats. [Abstract]

2023 Mar;17(3):241-250. PMID: 36751097
Exp Ther Med

Natural emodin reduces myocardial ischemia/reperfusion injury by modulating the RUNX1/miR‑142‑3p/DRD2 pathway and attenuating inflammation. [Abstract]

2022 Nov 7;24(6):745. PMID: 36561980
Am J Transl Res

Emodin reverses 5-Fu resistance in human colorectal cancer via downregulation of PI3K/Akt signaling pathway. [Abstract]

2020 May 15;12(5):1851-1861. PMID: 32509181

Emodin purchased from MedChemExpress. Usage Cited in: Am J Transl Res. 2020 May 15;12(5):1851-1861. [Abstract]

Emodin resensitizes SW480/5-Fu cells to 5-Fu. SW480/5-Fu cells are treated with 5-Fu or/and Emodin for 72 h. The proliferation of SW480/5-Fu cell is detected by Ki67 immunofluorescence.

Emodin purchased from MedChemExpress. Usage Cited in: Am J Transl Res. 2020 May 15;12(5):1851-1861. [Abstract]

Emodin reverses 5-Fu chemoresistance in CRC via downregulation of PI3K/Akt signaling pathway. SW480/5-Fu cells are treated with 5-Fu or/and Emodin for 72 h. Then, the protein expressions of Bax, Bcl-2, cleaved caspase3, ERK, Akt, p-ERK and p-Akt in SW480/5-Fu cells are investigated by Western-blot.
Res Sq

2026 Feb 27.
bioRxiv

2025 April 10.
Asian Basic and Applied Research Journal

2(2): 50-60, 2020.

Lösungsmittel & Löslichkeit

In Vitro:

Acetone : 10.87 mg/mL (40.22 mM; Need ultrasonic)

DMSO : 5.41 mg/mL (20.02 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Ethanol : < 1 mg/mL (insoluble)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.7004 mL

18.5021 mL

37.0041 mL

5 mM

0.7401 mL

3.7004 mL

7.4008 mL

10 mM

0.3700 mL

1.8502 mL

3.7004 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 0.5% CMC-Na/saline water

Solubility: 3.33 mg/mL (12.32 mM); Suspened solution; Need ultrasonic

Protocol 2

Add each solvent one by one: 0.5% Methyl cellulose/0.5% Tween-80 in Saline water

Solubility: 10 mg/mL (37.00 mM); Suspended solution; Need ultrasonic

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (282 KB)
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Korean - KR (396 KB)
- Portuguese - PT (396 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Tin-Yun Ho, et al. Emodin blocks the SARS coronavirus spike protein and angiotensin-converting enzyme 2 interaction. Antiviral Res. 2007 May;74(2):92-101. [Content Brief]

[2]. Stefania Sarno, et al. Toward the rational design of protein kinase casein kinase-2 inhibitors. Pharmacol Ther. Feb-Mar 2002;93(2-3):159-68. [Content Brief]

[3]. Ying Feng, et al. Emodin, a natural product, selectively inhibits 11beta-hydroxysteroid dehydrogenase type 1 and ameliorates metabolic disorder in diet-induced obese mice. Br J Pharmacol. 2010 Sep;161(1):113-26. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO / Acetone	1 mM	3.7004 mL	18.5021 mL	37.0041 mL	92.5104 mL
	5 mM	0.7401 mL	3.7004 mL	7.4008 mL	18.5021 mL
	10 mM	0.3700 mL	1.8502 mL	3.7004 mL	9.2510 mL
	15 mM	0.2467 mL	1.2335 mL	2.4669 mL	6.1674 mL
	20 mM	0.1850 mL	0.9251 mL	1.8502 mL	4.6255 mL
Acetone	25 mM	0.1480 mL	0.7401 mL	1.4802 mL	3.7004 mL
	30 mM	0.1233 mL	0.6167 mL	1.2335 mL	3.0837 mL
	40 mM	0.0925 mL	0.4626 mL	0.9251 mL	2.3128 mL

Emodin

42 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Emodin

Anti-Infection Compound Library

Cell Cycle/DNA Damage Compound Library

Immunology/Inflammation Compound Library

Kinase Inhibitor Library

Metabolism/Protease Compound Library

Stem Cell Signaling Compound Library

Wnt/Hedgehog/Notch Compound Library

Natural Product Library

Anti-Cancer Compound Library

Antiviral Compound Library

Autophagy Compound Library

Anti-Aging Compound Library

Anti-diabetic Compound Library

Lipid Compound Library

Medicine Food Homology Compound Library

Phenols Library

Traditional Chinese Medicine Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Gut Microbial Metabolite Library

Microbial Metabolite Library

Anti-Obesity Compound Library

Food-Sourced Compound Library

Rare Diseases Drug Library

Anti-Cancer Natural Product Library

Antiviral Traditional Chinese Medicine Active Compound Library

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

Plant-Sourced Natural Product Library

Human Metabolite Library

Cancer Stem Cells Compound Library

Metabolic Enzyme Compound Library

Mitochondrial Toxicity Compound Library

Highly Selective Inhibitors Library

Cell Death Library

Serine/Threonine Kinase Inhibitor Library

Multi-Target Compound Library

Bioactive Compound Library Max

Anti-Aging Compound Library Mini

Kinase Inhibitor Library Mini

Natural Product Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Anti-Brain Cancer Compound Library

Miao Ethnicity Medicine Compound Library

Tibetan Medicine Compound Library

PBCRBS Traditional Chinese Medicine Compound Library

Heat-Clearing and Detoxification Traditional Chinese Medicine Compound Library

Protein Kinase Compound Library

RO5 Drug-like Natural Product Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Ancient Chinese Classical Formulas Traditional Chinese Medicine Active Compound Library

Mass Spectrometry Human Metabolite Library

Antitussive and Antiasthmatic Traditional Chinese Medicine Active Compound Library

Diarrhea-Related Traditional Chinese Medicine Active Compound Library

Posttranslational Modification Library

Mongolian Medicine Compound Library

Quinones Library

Tonifying Traditional Chinese Medicine Monomer Compound Library

RNA Binding Bioactive Compound Library

Fungal-Sourced Compound Library

Mass Spectrometry Natural Product Library

Publications Citing Use of MedChemExpress (MCE) Emodin

Alle Casein Kinase Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (42)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Emodin Related Classifications

HY-14393 Related Classifications